Scarica l'app Stockscreener
24.26
0.86%
-0.21
Dopo l'orario di chiusura:
24.35
0.09
+0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$24.47
Aprire:
$24.59
Volume 24 ore:
33.39M
Relative Volume:
0.79
Capitalizzazione di mercato:
$137.93B
Reddito:
$62.46B
Utile/perdita netta:
$7.88B
Rapporto P/E:
17.58
EPS:
1.38
Flusso di cassa netto:
$11.22B
1 W Prestazione:
-4.30%
1M Prestazione:
+1.21%
6M Prestazione:
-8.93%
1 anno Prestazione:
-19.05%
Intervallo 1D:
$24.25
$24.65
Intervallo di 1 settimana:
$24.25
$25.44
Portata 52W:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.26 | 144.12B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Lobbying Update: $3,490,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade - The Motley Fool
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - AOL.com
What drives Pfizer Inc. stock priceFree Stock Market Return Analysis - Jammu Links News
Pfizer Inc. Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com
Can Pfizer Limited (PFIZER) Maintain Its ValuationFree Market Volatility Navigation Tips - Jammu Links News
Is Pfizer Inc. a good long term investmentOutstanding trading profits - jammulinksnews.com
What analysts say about Pfizer Inc. stockTremendous portfolio expansion - jammulinksnews.com
Pfizer’s Discounted Stock Offers Yield, But Risks Linger - Finimize
Sally Susman helped steer Pfizer through COVID-19. Her advice for leaders? Learn to write — and listen. - Business Insider
Pfizer’s (PFE) Dividend Safety: Balancing Innovation and Shareholder Returns - Yahoo Finance
Morgan Stanley Maintains a Hold on Pfizer (PFE) - MSN
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - MSN
Pfizer’s INLYTA® Study in Taiwan: Key Insights for Investors - TipRanks
Pfizer’s BeneFIX Study Update: Key Insights for Investors - TipRanks
Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer in Maternal Health - TipRanks
Pfizer’s Lyme Disease Vaccine Study: Key Insights for Investors - TipRanks
Pfizer’s Promising Phase 2 Study on Inotuzumab Ozogamicin for Pediatric Leukemia - TipRanks
Pfizer’s Rimegepant Study: A New Hope for Migraine Sufferers - TipRanks
Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention? - TipRanks
Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer in Infant RSV Prevention - TipRanks
Pfizer's Global Health Fellows Program: Leveraging Colleagues’ Expertise to Help Improve Healthcare Access Around the World - Pfizer
Pfizer’s Latest Study on PF-07799544: A Potential Game-Changer for Advanced Solid Tumors - TipRanks
Rx Rundown: Sarepta Therapeutics, Juul, Pfizer and more - Medical Marketing and Media
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
13 Cheap Stocks Under $50 to Buy Now - Insider Monkey
Pfizer, Lilly spend big on telehealth contracts: Lawmaker report - Sherwood News
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit - insights.citeline.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Just Reversed Its Bull Run. Is It A Buy Or A Sell? - Investor's Business Daily
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga
Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program - simplywall.st
Pfizer’s EPIC-Peds Study: A Potential Game-Changer for Pediatric COVID-19 Treatment - TipRanks
Pfizer’s Phase 1 Study on PF-07941944: Key Insights for Investors - TipRanks
Pfizer’s Pediatric Leukemia Study: Implications for BESPONSA’s Market Potential - TipRanks
Bristol Myers, Pfizer to offer Eliquis at a discount for some patients - BioPharma Dive
Major drugmakers offer big discount on blood thinner Eliquis - Fox Business
Bristol-Myers Squibb (BMY) and Pfizer (PFE) Stocks Jump on Eliquis Drug Discount - TipRanks
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters
Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Lifestyle Drugs Market Future Business Opportunities - openPR.com
How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest
Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg.com
BMS-Pfizer alliance to offer Eliquis at 40% discount to cash-paying patients - Investing.com Canada
Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan
Exclusive | Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount - The Wall Street Journal
Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours - Stocktwits
Pfizer’s Latest Clinical Study: A New Hope for Advanced Melanoma Treatment? - TipRanks
Pfizer’s INLYTA® Study Completion: Real-World Insights and Market Impact - TipRanks
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):